A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...

New details have emerged about what Regeneron is planning for the Saratoga Springs site it acquired last year.

Fintel reports that on November 12, 2025, Wolfe Research downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...

Global drug stocks rally as the FDA names Richard Pazdur, its top cancer drug regulator, as the head of its influential ...

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...

Williams & Connolly, a General Litigation Department of the Year finalist, notched several victories before the U.S. Supreme ...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today reported ...

Alvotech ( ($ALVO) ) has shared an announcement. On November 10, 2025, Alvotech announced that the UK High Court ruled in its favor, rejecting an ...

A well-tolerated antisense oligonucleotide yielded significant reductions in severe hypertriglyceridemia while lowering risk for acute pancreatitis in two phase 3 trials.

Chelsea Cirruzzo is a Washington correspondent at STAT, where she covers HHS. You can reach Chelsea on Signal at chelseacirruzzo.42. Daniel Payne reports on how the health industry and Washington ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...